Drug discovery

The Drug Discovery and Development Unit (DDD) focuses on innovative, disease-modifying drugs for treating degenerative disorders by targeting noxious protein-misfolding and aggregation in diabetes, Alzheimer's disease (tau), Parkinson's disease (α-synuclein), huntington, ...

reMYND's Drug Discovery & Development focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – cellular degeneration in patients suffering protein misfolding disorders, such as Alzheimer's and Parkinson's disease.

reMYND's pre-clinical pipeline of small molecules consists primarily of disease-modifying programs.